These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 11796313)
1. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Miyake H; Gleave M; Kamidono S; Hara I Urology; 2002 Jan; 59(1):150-4. PubMed ID: 11796313 [TBL] [Abstract][Full Text] [Related]
2. Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Hazzaa SM; Elashry OM; Afifi IK Pathol Oncol Res; 2010 Mar; 16(1):101-9. PubMed ID: 19757199 [TBL] [Abstract][Full Text] [Related]
3. Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder. Elsamman E; Fukumori T; Kasai T; Nakatsuji H; Nishitani MA; Toida K; Ali N; Kanayama HO BJU Int; 2006 Jun; 97(6):1202-7. PubMed ID: 16686711 [TBL] [Abstract][Full Text] [Related]
4. Expression of the human erythrocyte glucose transporter in transitional cell carcinoma of the bladder. Chang S; Lee S; Lee C; Kim JI; Kim Y Urology; 2000 Mar; 55(3):448-52. PubMed ID: 10699635 [TBL] [Abstract][Full Text] [Related]
5. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma. Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911 [TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Shiina H; Igawa M; Nagami H; Yagi H; Urakami S; Yoneda T; Shirakawa H; Ishibe T; Kawanishi M Cancer; 1996 Oct; 78(8):1762-74. PubMed ID: 8859190 [TBL] [Abstract][Full Text] [Related]
7. Analysis of factors predicting intravesical recurrence of superficial transitional cell carcinoma of the bladder without concomitant carcinoma in situ. Sakai I; Miyake H; Harada K; Hara I; Inoue TA; Fujisawa M Int J Urol; 2006 Nov; 13(11):1389-92. PubMed ID: 17083389 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508 [TBL] [Abstract][Full Text] [Related]
9. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881 [TBL] [Abstract][Full Text] [Related]
10. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression. Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057 [TBL] [Abstract][Full Text] [Related]
11. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer. Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323 [TBL] [Abstract][Full Text] [Related]
12. [Evaluation of HER2 protein overexpression in non-muscle-invasive bladder cancer with emphasis on tumour grade and recurrence]. Janane A; Hajji F; Ismail TO; Elondo JC; Ghadouane M; Ameur A; Abbar M; Bouzidi A Actas Urol Esp; 2011 Apr; 35(4):189-94. PubMed ID: 21419519 [TBL] [Abstract][Full Text] [Related]
13. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744 [TBL] [Abstract][Full Text] [Related]
14. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma. Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551 [TBL] [Abstract][Full Text] [Related]
15. Value of immunohistochemical laminin staining in transitional cell carcinoma of human bladder. Abou Farha KM; Janknegt RA; Kester AD; Arends JW Urol Int; 1993; 50(3):133-40. PubMed ID: 7682019 [TBL] [Abstract][Full Text] [Related]
16. [Correlation of clusterin expression to prognosis of bladder carcinoma]. Luo JH; Xie D; Chen W; Dai YP; Li XF; Tao Y; Zheng KL Ai Zheng; 2005 Jun; 24(6):743-7. PubMed ID: 15946493 [TBL] [Abstract][Full Text] [Related]
17. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder. Hara I; Miyake H; Hara S; Arakawa S; Kamidono S J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973 [TBL] [Abstract][Full Text] [Related]
18. Expression of beta-human chorionic gonadotropin (beta-hCG) in non-trophoblastic elements of transitional cell carcinoma of the bladder: possible relationship with the prognosis. Bacchi CE; Coelho KI; Goldberg J Rev Paul Med; 1993; 111(3):412-6. PubMed ID: 8108635 [TBL] [Abstract][Full Text] [Related]
19. Alterations in polymeric immunoglobulin receptor expression and secretory component levels in bladder carcinoma. Rossel M; Billerey C; Bittard H; Ksiazek P; Alber D; Revillard JP; Vuitton DA Urol Res; 1991; 19(6):361-6. PubMed ID: 1759330 [TBL] [Abstract][Full Text] [Related]